SCHEMBL1404705

SCHEMBL1404705

COc1c(N)cc(C(C)(C)C)cc1C(N)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARG P13631 1/20 0.38
RXRA P19793 1/20 0.38
PPARG P37231 1/20 0.38
ALDH1A1 P00352 3/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
GAA P10253 2/20 0.37
MAPT P10636 2/20 0.37
PKM P14618 1/20 0.37
RECQL P46063 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CFTR P13569 1/20 0.36
IKBKB O14920 1/20 0.36
KDM4E B2RXH2 4/20 0.36
GLA P06280 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 2/20 0.35
POLB P06746 2/20 0.35
TSHR P16473 1/20 0.35
APOBEC3A P31941 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL690623 0.90 RARG (0.41) RARGRXRAPPARGALDH1A1MEN1
SCHEMBL1600588 0.87 HSD17B10 (0.44) RARGRXRAPPARGALDH1A1MEN1
SCHEMBL1303731 0.85 CFTR (0.49) RARGRXRAPPARGALDH1A1MEN1
SCHEMBL688542 0.83 RARG (0.36) RARGRXRAPPARGALDH1A1MEN1
SCHEMBL5118526 0.83 MAPT (0.38) RARGRXRAPPARGALDH1A1MEN1
SCHEMBL690103 0.80 POLB (0.44) RARGRXRAPPARGALDH1A1MEN1
SCHEMBL690432 0.80 ALDH1A1 (0.36) RARGRXRAPPARGALDH1A1L3MBTL1
SCHEMBL690167 0.80 MAPT (0.38) RARGRXRAPPARGALDH1A1MEN1
SCHEMBL689665 0.80 MAPT (0.41) RARGRXRAPPARGALDH1A1MEN1
SCHEMBL690317 0.80 RARG (0.36) RARGRXRAPPARGALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7335657-B2 Cytokine inhibitors BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2008-02-26 US claimed
US-20060235017-A1 Cytokine Inhibitors BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-10-19 US claimed
EP-1631567-A2 HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2006-03-08 EP claimed
WO-2005016918-A2 HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-02-24 WO claimed
US-10941115-B2 Kinase inhibitors OXULAR ACQUISITIONS LIMITED (GB) 2021-03-09 US disclosed
EP-2981535-B1 UREA DERIVATIVES USEFUL AS KINASE INHIBITORS TOPIVERT PHARMA LTD (GB) 2020-12-16 EP disclosed
EP-3394059-B1 1-(3-TERT-BUTYL-PHENYL)-3-(4-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-6-YLOXY)-1,2,3,4-TETRAHYDRO- NAPHTHALEN-1-YL)-UREA DERIVATIVES AND THEIR USE AS P38 MAPK INHIBITORS CHIESI FARM SPA (IT) 2020-11-25 EP disclosed
US-20190330155-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2019-10-31 US disclosed
US-10435361-B2 Kinase inhibitors TOPIVERT PHARMA LIMITED (GB) 2019-10-08 US disclosed
US-10392346-B2 Kinase inhibitors TOPIVERT PHARMA LIMITED (GB) 2019-08-27 US disclosed
US-10125100-B2 Kinase inhibitors RESPIVERT LIMITED 2018-11-13 US disclosed
US-20180319748-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2018-11-08 US disclosed
US-7335657-B2 Cytokine inhibitors BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2008-02-26 US disclosed
US-20060235017-A1 Cytokine Inhibitors BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-10-19 US disclosed
EP-1692116-A1 1,2,3-TRIAZOLE AMIDE DERIVATIVES AS INHIBITORS OF CYTOKINE PRODUCTION BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2006-08-23 EP disclosed
US-7078419-B2 N-aryl-7-(pyridin-4yl-methyl-, oxy-, thio-or amino-)indole-2-carbonamide derivatives, e.g., 7-(2,6-Dimethyl-pyridin-4-yloxy)-1H-indole-2-carboxylic acid (5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenyl)-amide; treating chronic inflammatory diseases and anticoagulant or fibrinolytic therapy BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-07-18 US disclosed
EP-1631567-A2 HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2006-03-08 EP disclosed
US-20050153972-A1 1-[5-(5-tert-Butyl-2-methoxy-3-methylsulfamoyl-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazole-4-carboxylic acid (2,2-dimethyl-propyl)-amide; small molecule cytokine inhibitor; optimized efficacy, pharmacokinetic; antiinflammatory agent, osteoarthritis, asthma, gastrointestinal, respiratory disorder BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-07-14 US disclosed
WO-2005056535-A1 1,2,3-TRIAZOLE AMIDE DERIVATIVES AS INHIBITORS OF CYTOKINE PRODUCTION BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-06-23 WO disclosed
WO-2005016918-A2 HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180319748-A1 KINASE INHIBITORS LYN, SYK, BTK RARG 3912/4885RXRA 2296/4885PPARG 2968/4885
US-10125100-B2 Kinase inhibitors SYK, LYN, SRC RARG 3671/4885RXRA 1763/4885PPARG 4581/4885
US-20190330155-A1 KINASE INHIBITORS SYK, LYN, BTK RARG 3746/4885RXRA 1377/4885PPARG 4581/4885
US-20050153972-A1 1-[5-(5-tert-Butyl-2-methoxy-3-methylsulfamoyl-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazole-4-carboxylic acid (2,2-dimethyl-propyl)-amide; small molecule cytokine inhibitor; optimized efficacy, pharmacokinetic; antiinflammatory agent, osteoarthritis, asthma, gastrointestinal, respiratory disorder IL1A, IL1R1, IL1RN RARG 1699/4885RXRA 757/4885PPARG 423/4885
US-10941115-B2 Kinase inhibitors SYK, LYN, BTK RARG 3746/4885RXRA 1377/4885PPARG 4581/4885
US-10392346-B2 Kinase inhibitors LYN, SYK, BTK RARG 3912/4885RXRA 2296/4885PPARG 2968/4885
US-10435361-B2 Kinase inhibitors SYK, LYN, BTK RARG 3974/4885RXRA 1759/4885PPARG 4638/4885
US-20060235017-A1 Cytokine Inhibitors IL1B, IL1A, IL1R1 RARG 2023/4885RXRA 1274/4885PPARG 2667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.